Lagerstedt and Stenkula receive Novo Seed Grant
Antidiabetics that also provide cardiovascular benefit is a key unmet need in diabetes treatment. ApoA-l is a protein shown to have both glucose lowering and cholesterol-lowering effects and has been investigated by Jens Lagerstedt and Karin Stenkula for its therapeutic potential. They have now received 2,5 million Danish kroner from the Novo Seeds for taking innvoation a step further. The goal is
https://www.ludc.lu.se/article/lagerstedt-and-stenkula-receive-novo-seed-grant - 2025-11-19
